Clinical trial Recruiting at 1 site Interventional Ages 18 and up

A new system to improve care for hospitalized patients with cirrhosis

Official title: Pragmatic Randomized Controlled Trial to Evaluate the Effect of CirrhosisRx, a Novel Clinical Decision Support System, on Guideline-adherence and Clinical Outcomes for Patients With Cirrhosis

Run by University of California, San Francisco · NCT05967273 · Data updated 2026-11-12

This study is testing a new support system called CirrhosisRx to see if it can help doctors provide better care for hospitalized patients with cirrhosis compared to regular treatment.

More Cirrhosis trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment2106 (estimated)
SponsorUniversity of California, San Francisco
Academic / other
Locations1 site (San Francisco, California)
StatusRecruiting
StartedJanuary 14, 2025
Main results expectedJanuary 2027
Study endsJanuary 2027
Registry record updatedNovember 5, 2026
Trial IDNCT05967273 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adult patients aged 18 and older with a history of cirrhosis as defined by specific diagnostic codes.

Probably not a fit

Patients who are under 18 years old or do not meet the cirrhosis definition criteria will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of CirrhosisRx, a clinical decision support system designed specifically for inpatient care of cirrhosis patients, compared to standard care practices. With over 200,000 hospitalizations for cirrhosis annually in the U.S., and significant rates of readmission and mortality, the study seeks to determine if the CirrhosisRx system can enhance adherence to national quality measures and improve clinical outcomes. The approach involves a pragmatic randomized controlled trial where treatment teams will be randomly assigned to use either the CirrhosisRx system or continue with usual care. This innovative method addresses existing gaps in cirrhosis management and aims to provide evidence on the effectiveness of CDS systems in this context.

Why it matters

Potential benefit: If successful, this system could significantly improve the quality of care and outcomes for hospitalized patients with cirrhosis.

How similar studies have gone: While clinical decision support systems have shown promise in other areas of healthcare, their application in cirrhosis care remains largely untested, making this approach novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* All adult (age ≥ 18 years) patients who have cirrhosis identified based on 1+ chronic liver disease and 1+ cirrhosis (or its complications) International Classification of Diseases, Revision 10 diagnosis codes OR mention of cirrhosis or portal hypertension (or their complications) in clinical documentation admitted at our institution.

Exclusion Criteria:

* Children (age \< 18 years)
* patients who do not meet the cirrhosis definition criteria as noted above
* ambulatory patients

Where it's running

  • University of California San Francisco Medical Center
    San Francisco, California, United States
    Recruiting

Study contacts

  • Principal investigator: Jin Ge, MD, MBA — University of California, San Francisco
  • Study coordinator: Jin Ge, MD, MBA
  • Email: jin.ge@ucsf.edu
  • Phone: 415-502-8070

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.